July 12, 2024

426c.Mod.Core-C4b adjuvanted with 3M-052-AF + Alum immunization in combination with an antiretroviral analytical treatment interruption (ATI) in people living with HIV for elicitation of VRC01-lineage antibodies

Study Information:
  • Are you 18-60 years of age living with HIV, and want to be a part of a vaccine study?
  • Is your viral load suppressed/undetectable?
  • Are you able to receive a vaccine?
  • Are you generally healthy?
  • Are you willing to temporarily stop taking antiretrovirals?

You may qualify for a study looking at testing an experimental HIV vaccine with an experimental adjuvant to see how the immune responses change among participants who do an antiretroviral analytical treatment interruption (ATI) compared to those who do not. Compensation at each study visit will be provided for time and travel. Transportation services are also available upon request. If interested, please email sspaulding@uabmc.edu.